Dihydro-1H-pyrrolo[1,2-a]thiazolo[3,4-d]pyrazine-5,8,10(3H,5aH,10aH)-trione

Catalog No. :
ACLWHT826
CAS No. :
161771-76-2
Molecular Formula :
C9H10N2O3S
Molecular Weight :
226.26

IUPAC Name:tetrahydro-3H,5H,10H-pyrrolo[1,2-a]thiazolo[3,4-d]pyrazine-5,8,10(5aH)-trione

Dihydro-1H-pyrrolo[1,2-a]thiazolo[3,4-d]pyrazine-5,8,10(3H,5aH,10aH)-trione structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100mg97%$658.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameDihydro-1H-pyrrolo[1,2-a]thiazolo[3,4-d]pyrazine-5,8,10(3H,5aH,10aH)-trione
IUPAC Nametetrahydro-3H,5H,10H-pyrrolo[1,2-a]thiazolo[3,4-d]pyrazine-5,8,10(5aH)-trione
Molecular FormulaC9H10N2O3S
Molecular Weight226.26
SMILESO=C(N1C2CSC1)C(CCC3=O)N3C2=O
InChI KeyHLWTZCIFAMNMKX-UHFFFAOYSA-N
Synonym1H,3H,5H-pyrrolo[1,2-a]thiazolo[3,4-d]pyrazine5,8,10(5aH,10aH)-trione,dihydro-;Pidotimod Impurity 25;PidotiMod Diketopiperazine Dihydro-1H,3H,5H-pyrrolo[1,2-a]thiazolo[3,4-d]pyrazine-5,8,10(5ah,10ah)-trione;PidotiMod IMp.Y;Pidotimod Impurity Z;Dihydro-1H,5H-pyrrolo[1,2-a][1,3]thiazolo[3,4-d]pyrazine-5,8,10(5aH,10aH)-trione;dihydro-1H-pyrrolo[1,2-a]thiazolo[3,4-d]pyrazine-5,8,10(3H,5aH,10aH)-trione;Pidomod impurity Y
CAS No.161771-76-2

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P305+P351+P338

Synthetic Route by SureRoute

1. ACLWHT826 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACLWHT826 route product structure diagram
    ACLWHT826161771-76-2
Inquiry

2. ACLWHT826 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACLWHT826 route product structure diagram
    ACLWHT826161771-76-2
Inquiry

Comments (0)